Robert Zalewski-Zaragoza, MD

Articles by Robert Zalewski-Zaragoza, MD

Esketamine Safety Mechanisms and Bioavailability

ByGeoffrey Grammer, MD,Harman Deol, MD,William M. Sauve, MD,Robert Zalewski-Zaragoza, MD

August 8th 2024

Geoffrey Grammer, MD closes this series highlighting the administration options of esketamine, its safety profile, and the importance of monitoring patients using this treatment.

Robert Zalewski-Zaragoza, MD, presenting slides

Esketamine for TRD: MOA, Application, and Adverse Events

ByGeoffrey Grammer, MD,Harman Deol, MD,William M. Sauve, MD,Robert Zalewski-Zaragoza, MD

August 8th 2024

Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.

Treatment Options for TRD

ByGeoffrey Grammer, MD,Harman Deol, MD,William M. Sauve, MD,Robert Zalewski-Zaragoza, MD

August 8th 2024

William Sauve, MD shares the growing landscape of treatments for treatment resistant depression (TRD) and their mechanism of action, such as brain stimulation through electroconvulsive therapy or medication such as esketamine.

Impact and Costs of Treatment Resistant Depression

ByGeoffrey Grammer, MD,Harman Deol, MD,William M. Sauve, MD,Robert Zalewski-Zaragoza, MD

August 8th 2024

Harman Deol, MD begins this series presenting an overview of treatment resistant depression (TRD), highlighting its prevalence along with its impact on patients and the healthcare system.